Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration
ISRN Ophthalmology · 2011
DOI: 10.5402/2011/916789 ↗Kurz gefasst
Fachartikel in der Zeitschrift ISRN Ophthalmology, 2011. Verfasst von Kisaburo Yamada und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine, Oita University, Hasama-machi, Yufu-shi, Oita 879-5593, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Purpose
To report our experiences in patients with age-related macular degeneration (AMD) treated initially with intravitreal ranibizumab and then switched to bevacizumab.
Methods
We retrospectively reviewed the records of 7 patients (7 eyes) who were treated with monthly injections of intravitreal ranibizumab and then switched to injections of bevacizumab (every 6 weeks) for six months. The best-corrected visual acuity measurements (BCVA) and optical coherence tomography (OCT) were performed at the baseline examination and then at each visit. The Wilcoxon signed-rank test was used for the statistical analysis.
Results
Following three monthly ranibizumab treatments, there was no significant difference in the BCVA, while the foveal retinal thickness (FRT) significantly decreased (). Switching from ranibizumab to bevacizumab resulted in maintenance (57.2%) of the BCVA and a further decrease in the FRT () after 6 months.
Conclusions
Switching to intravitreal bevacizumab may be effective in patients who wish to discontinue intravitreal ranibizumab treatment due to the high cost.
Autor:innen und Institutionen
- Department of Ophthalmology, Faculty of Medicine, Oita University, Hasama-machi, Yufu-shi, Oita 879-5593, Japan.
Zitieren
APA
Yamada, K., Kimoto, K., Kono, H., & Kubota, T. (2011). Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration. ISRN Ophthalmology. https://doi.org/10.5402/2011/916789
Vancouver
Yamada K, Kimoto K, Kono H, Kubota T. Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration. ISRN Ophthalmology. 2011. doi:10.5402/2011/916789
BibTeX
@article{Yamada2011,
author = {Yamada, Kisaburo and Kimoto, Kenichi and Kono, Hirofumi and Kubota, Toshiaki},
title = {Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration},
journal = {ISRN Ophthalmology},
year = {2011},
doi = {10.5402/2011/916789}
}
EUVIMED